Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4)

Peptides

Volumn 31, Issue 6, 2010, Pages 1194-1204

  Volta, Mattia ^a   Marti, Matteo ^a   McDonald, John ^b   Molinari, Stefano ^a   Camarda, Valeria ^a   Pelà, Michela ^a   Trapella, Claudio ^a   Morari, Michele ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

6 Hydroxydopamine; GF 4; Microdialysis; Nociceptin orphanin FQ; NOP receptor knock out; Parkinson's disease

Indexed keywords

1 [1 CYCLOOCTYLMETHYL 5 (1 HYDROXY 1 METHYLETHYL) 1,2,3,6 TETRAHYDROPYRIDIN 4 YL] 3 ETHYL 1,3 DIHYDROBENZOIMIDAZOL 2 ONE; 4 AMINOBUTYRIC ACID; ANTIPARKINSON AGENT; GF 4; GLUTAMIC ACID; GLUTATHIONE; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR ANTAGONIST; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

AKINESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYKINESIA; CALCIUM MOBILIZATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FACILITATION; GAIT DISORDER; MALE; MEMBRANE BINDING; MOTOR PERFORMANCE; MOUSE; NEUROMODULATION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN SECRETION; RECEPTOR BLOCKING; THALAMUS; WILD TYPE;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BENZIMIDAZOLES; CHO CELLS; CRICETINAE; CRICETULUS; CYCLOOCTANES; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; OXIDOPAMINE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID;

MUS; PARKINSONIA; RATTUS;

EID: 77952102139     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.03.015     Document Type: Article

References (43)

1. Bigoni R., Giuliani S., Calò G., Rizzi A., Guerrini R., Salvadori S., et al. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol 359 (1999) 160-167
2. Brown J.M., Gouty S., Iyer V., Rosenberger J., and Cox B.M. Differential protection against MPTP or metamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression. J Neurochem 98 (2006) 495-505
3. qi5. Naunyn Schmiedebergs Arch Pharmacol 379 (2009) 599-607
4. Calò G., Rizzi A., Rizzi D., Bigoni R., Guerrini R., Marzola G., et al. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 136 (2002) 303-311
5. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
6. Currò D., Yoo J.H., Anderson M., Song I., Del Valle J., and Owyang C. Molecular cloning of the orphanin FQ receptor gene and differential tissue expression of splice variants in rat. Gene 266 (2001) 139-145
7. Deniau J.M., and Chevalier G. Disinhibition as a basic process in the expression of striatal functions. II. The striato-nigral influence on thalamocortical cells of the ventromedial thalamic nucleus. Brain Res 334 (1985) 227-233
8. + and 6-OHDA lesioned rats. Neuropharmacology 56 (2009) 761-767
9. Fischetti C., Camarda V., Rizzi A., Pelà M., Trapella C., Guerrini R., et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor nonpeptide antagonist Compound 24. Eur J Pharmacol 614 (2009) 50-57
10. Goto Y., Arai-Otsuki S., Tachibana Y., Ichikawa D., Ozaki S., Takahashi H., et al. Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J Med Chem 49 (2006) 847-849
11. Guerrini R., Calò G., Rizzi A., Bianchi C., Lazarus L.H., Salvadori S., et al. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem 40 (1997) 1789-1793
12. Kenakin T. A pharmacology primer (2004), Elsevier Academic, San Diego
13. Kitayama M., Barnes T.A., Carra G., Calò G., Guerrini R., Rowbotham D.J., et al. Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2. Naunyn Schmiedebergs Arch Pharmacol 368 (2003) 528-537
14. Klockgether T., Turski L., Schwarz M., and Sontag K.H. Motor actions of excitatory amino acids and their antagonists within the rat ventromedial thalamic nucleus. Brain Res 399 (1986) 1-9
15. Kuschinsky K., and Hornykiewicz O. Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur J Pharmacol 19 (1972) 119-122
16. Lambert D.G. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 7 (2008) 694-710
17. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
18. Marti M., Guerrini R., Beani L., Bianchi C., and Morari M. Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat. Neuroscience 112 (2002) 153-160
19. Marti M., Mela F., Veronesi C., Guerrini R., Salvadori S., Federici M., et al. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulate stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci 24 (2004) 6659-6666
20. Marti M., Mela F., Guerrini R., Calò G., Bianchi C., and Morari M. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem 91 (2004) 1501-1504
21. Marti M., Mela F., Fantin M., Witta J., Di Benedetto M., Buzas B., et al. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci 95 (2005) 9591-9601
22. Marti M., Trapella C., Viaro R., and Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and l-DOPA additively attenuate experimental Parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci 27 (2007) 1297-1307
23. Marti M., Trapella C., and Morari M. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with l-DOPA. J Neurochem 107 (2008) 1683-1696
24. McClanahan R.H., Huitric A.C., Pearson P.G., Desper J.C., and Nelson S.D. Evidence for a cyotchrome P-450 catalyzed allylic rearrangement with double bond topomerization. J Am Chem Soc 110 (1988) 1979-1981
25. McDonald J., Calò G., Guerrini R., and Lambert D.G. UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 183-187
26. McFarland N.R., and Haber S.N. Thalamic relay nuclei of the basal ganglia form both reciprocal and nonreciprocal cortical connections, linking multiple frontal cortical areas. J Neurosci 22 (2002) 8117-8132
27. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
28. Norton C.S., Neal C.R., Kumar S., Akil H., and Watson S.J. Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems. J Comp Neurol 444 (2002) 358-368
29. Nyitrai G., Szàrics E., Kovàcs I., Kékesi K.A., Juhàsz G., and Kardos J. Effect of CGP 36742 on the extracellular level of neurotransmitter amino acids in the thalamus. Neurochem Int 34 (1999) 391-398
30. Ozaki S., Kawamoto H., Itoh Y., Miyagi M., Azuma T., Ichikawa D., et al. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol 402 (2000) 45-53
31. Pan Y.X., Xu J., Wan B.L., Zuckerman A., and Pasternak G.W. Identification and differential regional expression of KOR-3/ORL-1 gene splice variants in mouse brain. FEBS Lett 435 (1998) 65-68
32. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1982), Academic Press, Sydney
33. Redrobe J.P., Calò G., Regoli D., and Quirion R. Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn Schmiedebergs Arch Pharmacol 365 (2002) 164-167
34. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., et al. Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 270 (1995) 792-794
35. Rozas G., Guerra M.J., and Labandeira-Garcia J.L. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2 (1997) 75-84
36. Schallert T., De Ryck M., Whishaw I.Q., Ramirez V.D., and Teitelbaum P. Excessive bracing reactions and their control by atropine and l-DOPA in an animal analog of parkinsonism. Exp Neurol 64 (1979) 33-43
37. Shinkai H., Ito T., Iida T., Kitao Y., Yamada H., and Uchida I. 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity. J Med Chem 43 (2000) 4667-4677
38. Spagnolo B., Carrà G., Fantin M., Fischetti C., Hebbes C., McDonald J., et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. J Pharmacol Exp Ther 321 (2007) 961-967
39. Trapella C., Guerrini R., Piccagli L., Calò G., Carrà G., Spagnolo B., et al. Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg Med Chem 14 (2006) 692-704
40. Viaro R., Sanchez-Pernaute R., Marti M., Trapella C., Isacson O., and Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis 30 (2008) 430-438
41. Viaro R, Marti M, Morari M. Dual motor response to l-DOPA and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: paradoxical inhibition is relieved by D(2)/D(3) receptor blockade. Exp Neurol; doi:10.1016/j.expneurol.2010.01.014.
42. Visanji N.P., de Bie R.M., Johnston T.H., McCreary A.C., Brotchie J.M., and Fox S.H. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 23 (2008) 1922-1925
43. Zaratin P.F., Petrone G., Sbacchi M., Garnier M., Fossati C., Petrillo P., et al. Modification of nociceptin and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J Pharmacol Exp Ther 308 (2004) 454-461